Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |4 March 2008

Drug Treatment for Patients with Dementia: American College of Physicians and American Academy of Family Physicians Recommendations Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full reports titled “Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians” and “Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline.” They are in the 4 March 2008 issue of Annals of Internal Medicine (volume 148, pages 370-378 and pages 379-397). The first report was written by A. Qaseem, V. Snow, J.T. Cross Jr., M.A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, P. Santaguida, D.K. Owens, and the Joint American College of Physicians/American Academy of Family Physicians Panel on Dementia; the second report was written by P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
    • Who developed these recommendations?
    • What is the problem and what is known about it so far?
    • How did the ACP and the AAFP develop these recommendations?
    • What did the authors find?
    • What do the ACP and the AAFP suggest that patients and doctors do?
    • What are the cautions related to these recommendations?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

Who developed these recommendations?

The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) developed these recommendations. Members of the ACP are internists—specialists in the care of adults.

What is the problem and what is known about it so far?

Dementia affects memory and thinking enough to interfere with normal daily activities. About 1 out of every 10 Americans older than 65 years has some degree of dementia. Poor memory alone is not dementia, and some declines in short-term memory are normal as people age. Several conditions can cause dementia, but the 2 most common diseases are Alzheimer disease and cerebrovascular disease. In Alzheimer disease, build-up of abnormal proteins damages brain cells. In cerebrovascular disease, low blood flow to the brain damages brain cells. There is no cure for dementia. However, the U.S. Food and Drug Administration has approved 5 drugs that can modestly slow the worsening of dementia in some patients. Four of them belong to a class of drugs called cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine). The fifth drug, memantine, belongs to a class of drugs called neuropeptide-modifying agents. These drugs cannot cure dementia, can be costly, and can have side effects. It is uncertain how they can best be used to improve health outcomes for people with dementia.

How did the ACP and the AAFP develop these recommendations?

The authors reviewed published trials that compared 1 of the 5 drugs with no drug treatment or with another of the 5 drugs. They collected information from these trials on the benefits and side effects of each drug. The benefits included improvement in cognitive function (thinking and memory), global function (ability to do usual activities), behavior, quality of life, and caregiver burden. Harms included any unwanted symptom that was possibly related to the drug.

What did the authors find?

Fifty-nine studies met the authors' criteria for inclusion. Most trials of the 5 dementia drugs showed statistical improvements in measures of thinking and memory, but the improvements were generally too small to lead to clinically important improvements in the daily lives of patients and their caregivers. Outcomes related to behavior and quality of life were studied less frequently and did not show consistent improvements with the drugs. Studies of tacrine were weaker than studies of other drugs. Tacrine also had more side effects than the other drugs. Most studies were short (less than 12 months). Only 3 of the studies compared 1 of the dementia drugs with another, and these showed no differences. The most common side effects were gastrointestinal symptoms, such as nausea.

What do the ACP and the AAFP suggest that patients and doctors do?

Doctors, patients, and caregivers should consider the patient's situation and preferences when deciding whether to try 1 of the 5 available dementia drugs. Because there is not enough information that compares the effectiveness of 1 drug with that of another, doctors and patients should consider side effects, ease of use, and cost when choosing from the 5 drugs approved for treating dementia. Doctors and patients should advocate for more research on drugs to treat dementia.

What are the cautions related to these recommendations?

These recommendations may change when new studies become available.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Drug Treatment for Patients with Dementia: American College of Physicians and American Academy of Family Physicians Recommendations. Ann Intern Med. 2008;148:I–41. doi: 10.7326/0003-4819-148-5-200803040-00002

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2008;148(5):I-41.

DOI: 10.7326/0003-4819-148-5-200803040-00002

©
2008 American College of Physicians
0 Citations

See Also

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
View MoreView Less

Related Articles

Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians
Annals of Internal Medicine; 166 (6): 430-437
Annals for Educators - 21 March 2017
Annals of Internal Medicine; 166 (6): ED6
Annals for Educators - 17 April 2018
Annals of Internal Medicine; 168 (8): ED8
Annals for Educators - 4 April 2017
Annals of Internal Medicine; 166 (7): ED7
View MoreView Less

Journal Club

Review: In HF with preserved EF, β-blockers reduced mortality; drug treatment overall did not
Annals of Internal Medicine; 167 (12): JC68
Review: In older persons at vascular risk, statins do not prevent dementia or cognitive decline at 3.5 to 5 years
Annals of Internal Medicine; 164 (8): JC42
Review: Brief screening tests for dementia have pooled sensitivity of 76% to 92% and specificity of 81% to 91%
Annals of Internal Medicine; 163 (8): JC10
Review: In patients with dementia who live in care homes, some nondrug interventions reduce agitation
Annals of Internal Medicine; 162 (12): JC3
View MoreView Less

Related Point of Care

Smoking Cessation
Annals of Internal Medicine; 164 (5): ITC33-ITC48
Dementia
Annals of Internal Medicine; 161 (3): ITC1
Dementia
Annals of Internal Medicine; 148 (7): ITC4-1
Osteoporosis
Annals of Internal Medicine; 167 (3): ITC17-ITC32
View MoreView Less

Related Topics

Dementia
Neurology

Dementia, Neurology.

PubMed Articles

Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication.
Cochrane Database Syst Rev 2018;
Therapeutic potential of vitamin E and its derivatives in traumatic brain injury-associated dementia.
Neurol Sci 2018.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×